Stocks · News reference

ProQR Therapeutics shares are trading higher after B of A Securities initiated its coverage on the stock with a Buy rating and announced a price target of $8.

Aug 20, 2026, 3:05 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 20, 2026, 12:06 PMAvi Kapoor
Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.
Read original at benzinga
AGEN COTY HBB JBSS KC
BenzingaAug 20, 2026, 12:03 PMBenzinga Newsdesk
B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8
B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $8.
Read original at benzinga
PRQR
BenzingaAug 13, 2026, 12:12 PMBenzinga Newsdesk
ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 25 percent increase over losses of $(0.12) per share from
Read original at benzinga
PRQR